Ashland Global (ASH)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
$72.93-0.37%
Close 2026-09-04 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Ashland aims to grow revenue to about $1.85 billion in fiscal 2026. Profit margins target adjusted EBITDA near $385-$400 million. Free cash flow conversion is focused at 50% of adjusted EBITDA. The company shows stable management and progress on revenue despite some margin pressure.
Profit margins are under pressure with adjusted EBITDA down to $98 million in Q2 from $108 million last year. Revenue growth is slow at 1% year-over-year. The company remains loss-making and faces sector headwinds.
The price is about 1% below our fair value near $67, in line with the Street median. Analysts expect about 5% revenue growth, which is slightly above current growth trends. Our view is cautious on margin recovery but aligned on revenue.
Breaks if: adjusted EBITDA falls below $385 million in FY26
Maintain full-year fiscal 2026 Adjusted EBITDA guidance of $385 to $400 million despite operational challenges.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround opportunity in the Materials sector. ASH is currently navigating a mix of operational improvements and challenges, with a focus on achieving specific revenue and EBITDA targets in the coming fiscal year.
The market appears to have priced in a justified valuation, with a low expectations gap. ASH is trading at a premium compared to peers, reflecting the market's view on its potential despite recent earnings misses.
Management is on track to meet its revenue goals, but the Adjusted EBITDA target remains mixed due to operational challenges. The near-term risk of missing earnings is low, but ASH has a history of consecutive misses that could affect investor sentiment.
The long-term thesis hinges on management's ability to maintain guidance and deliver on financial targets. Additionally, sector performance, particularly from key players like LIN, SHW, and ECL, will be crucial in shaping ASH's trajectory.
The most important moves since the prior daily snapshot.
Signal changed from 'cautious' to 'mixed'.
Mixed, the news cuts both ways. Ashland launched a new intestinal permeation enhancer for oral drugs. This aligns with its innovation strategy and growth objectives. However, the company missed earnings expectations in its latest report. This earnings miss raises concerns about its performance and outlook.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 4 of last 4 quarters. Adjusted EBITDA improved from $58 million in 2026-Q1 to $109 million in 2026-Q3, showing recovery despite operational challenges. Management has consistently reaffirmed the $385-$400 million full-year Adjusted EBITDA guidance, reflecting mixed but improving delivery.
“Reaffirming full-year fiscal 2026 Adjusted EBITDA guidance of $385-$400 million.”
“Updating full-year fiscal 2026 Adjusted EBITDA guidance to $385-$400 million.”
“Narrowing full-year fiscal 2026 Adjusted EBITDA guidance to $400-$420 million.”
“Issuing guidance for fiscal 2026 Adjusted EBITDA of $400 million to $420 million.”
Ashland targets Adjusted EBITDA between $385 million and $400 million for fiscal 2026.
Breaks if: free cash flow conversion falls below 40% in FY26
Breaks if: annual revenue falls below $1.835 billion in FY26
Maintain full-year fiscal 2026 sales guidance of $1,835 to $1,870 million with focus on organic growth and portfolio strength.
Stated as a priority in 4 of last 4 quarters. Revenue grew from $386 million in 2026-Q1 to $497 million in 2026-Q3, a 29% increase. Management has consistently reaffirmed the full-year fiscal 2026 sales guidance of $1,835 to $1,870 million, indicating delivery on this growth priority.
“Reaffirming full-year fiscal 2026 sales guidance of $1,835-$1,870 million.”
“Updating full-year fiscal 2026 sales guidance to $1,835-$1,870 million.”
“Narrowing full-year fiscal 2026 sales guidance to $1,835 million to $1,905 million.”
“Issuing guidance for fiscal 2026 sales of $1,835 million to $1,905 million.”
Overall, ASH's position is stable but requires careful monitoring of management execution and sector trends. Not investment advice.